ATAI News and Press, ATAI Life Sciences N.V. From 05/19/23

Last year, the Stanley Brothers signed a partnership between a professional sports league and a hemp/marijuana brand, becoming the first to do so. Prior to this, the company’s CBD products, including Charlotte’s Web, had been gaining popularity in Colorado, especially after a sur...

Studies have, in the past, associated the dilation of pupils, unexpected saccades and trippy details with the consumption of drugs such as DMT, psilocybin mushrooms and LSD. Now, a new case study has established a link between human vision and psychedelic substances. This may be the first study...

2023-05-11 09:23:10 ET ATAI Life Sciences press release ( NASDAQ: ATAI ): Q1 GAAP EPS of -$0.21 in-line. Revenue of $0.04M. Cash and cash equivalents and short-term investments totaled $249.9 million as of March 31, 2023, compared to $273.1 million of December 31, 2022...

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD data from the completed Phase 1 study, which suggest the potential for anxiolytic effects without the significant sedative effects seen with benzodiazep...

A recent study has found combining psychedelics and sex may offer individuals an enhanced mental and physical pleasure experience. A new series, titled “PSYC Taboo,” will explore the potential for mind-blowing orgasms and solo psychedelic experiences, as more people try alternativ...

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the ...

- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-s...

This year, the U.S. government will decide whether to approve the use of psychedelic drugs such as MDMA for the treatment of a range of mental health conditions. This milestone will not only be significant for patients in need of alternative therapies but also major players in the industry, inc...

2023-04-20 08:55:00 ET With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (NASDAQ: ATAI) is having a rough go of things lately. Nonetheless, per bombastic predictions by Wall Street analysts,...

The psychedelic renaissance is here, with numerous studies showing that psychedelics, including LSD, psilocybin, MDMA and ketamine. may be useful in the treatment of mental health conditions , such as addiction, depression, anxiety and psychological distress. Veteran religion journalist Don La...